Ginkgo Bioworks Holdings, Inc. (DNA)
NYSE:DNA
Want to see DNA full AI Analyst Report?
DNA Stock Chart & Stats
$8.86
-$0.35(-3.13%)
At close: 4:00 PM EST
$8.86
-$0.35(-3.13%)
Day’s Range― - ―
52-Week Range$5.37 - $17.58
Previous CloseN/A
Volume618.97K
Average Volume (3M)1.16M
Market Cap
$477.98M
Enterprise Value$744.03M
Total Cash (Recent Filing)$422.62M
Total Debt (Recent Filing)$417.08M
Price to Earnings (P/E)―
Beta2.78
Next Earnings
May 13, 2026EPS Estimate
-1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding49,941,880
10 Day Avg. Volume1,104,025
30 Day Avg. Volume1,156,060
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)2.71
P/FCF Ratio-2.58
Enterprise Value/Market Cap1.56
Enterprise Value/Revenue4.37
Enterprise Value/Gross Profit5.37
Enterprise Value/Ebitda-3.45
Forecast
1Y Price Target
$8.50Price Target Upside-4.06% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)-4.43
Revenue Forecast (FY)$159.47M
Bulls Say, Bears Say
Bulls Say
Capital AllocationDivestiture proceeds redirected toward higher-margin autonomous systems and the data and AI platform could strengthen the company’s revenue mix and margin profile.
Financial TrajectoryNarrowing adjusted losses and reduced cash burn signal improving financial health, which can extend the runway for strategic investments and partnerships.
Strategic DivestiturePlanned sale of the noncore Biosecurity unit allows the company to concentrate resources on its AI and autonomous laboratory strategy, potentially improving operational focus and execution.
Bears Say
Execution RiskAnalysts express concern that the pivot to building autonomous robotic labs lacks a clear commercial path and needs more visible progress on execution to justify expectations.
Profitability TimelineOngoing cash burn alongside unclear timelines for reaching breakeven and limited confidence in cost-cutting measures raise doubts about when the company will become profitable.
Revenue VisibilitySuspension of revenue guidance and the absence of growth forecasts create low visibility, making future sales performance difficult to forecast and increasing investor uncertainty.
Ginkgo Bioworks Holdings News
DNA FAQ
What was Ginkgo Bioworks Holdings, Inc.’s price range in the past 12 months?
Ginkgo Bioworks Holdings, Inc. lowest stock price was $5.37 and its highest was $17.58 in the past 12 months.
What is Ginkgo Bioworks Holdings, Inc.’s market cap?
Ginkgo Bioworks Holdings, Inc.’s market cap is $477.98M.
When is Ginkgo Bioworks Holdings, Inc.’s upcoming earnings report date?
Ginkgo Bioworks Holdings, Inc.’s upcoming earnings report date is May 13, 2026 which is in 22 days.
How were Ginkgo Bioworks Holdings, Inc.’s earnings last quarter?
Ginkgo Bioworks Holdings, Inc. released its earnings results on Feb 26, 2026. The company reported -$1.41 earnings per share for the quarter, beating the consensus estimate of -$1.455 by $0.045.
Is Ginkgo Bioworks Holdings, Inc. overvalued?
According to Wall Street analysts Ginkgo Bioworks Holdings, Inc.’s price is currently Overvalued.
Does Ginkgo Bioworks Holdings, Inc. pay dividends?
Ginkgo Bioworks Holdings, Inc. does not currently pay dividends.
What is Ginkgo Bioworks Holdings, Inc.’s EPS estimate?
Ginkgo Bioworks Holdings, Inc.’s EPS estimate is -1.21.
How many shares outstanding does Ginkgo Bioworks Holdings, Inc. have?
Ginkgo Bioworks Holdings, Inc. has 49,941,880 shares outstanding.
What happened to Ginkgo Bioworks Holdings, Inc.’s price movement after its last earnings report?
Ginkgo Bioworks Holdings, Inc. reported an EPS of -$1.41 in its last earnings report, beating expectations of -$1.455. Following the earnings report the stock price went down -30.484%.
Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings, Inc.?
Currently, no hedge funds are holding shares in DNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ginkgo Bioworks Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$8.50 (-4.06% Downside)
$8.50 (-4.06% Downside)
Blogger Sentiment
Neutral
DNA Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 88.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.29%
12-Months-Change
Fundamentals
Return on Equity
-53.72%
Trailing 12-Months
Asset Growth
-18.71%
Trailing 12-Months
Company Description
Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
DNA Company Deck
DNA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented several strong strategic and operational positives: validated autonomous lab technology (OpenAI result, PNNL $47M deal), meaningful facility scale-up (Nebula), and substantial cost and cash-burn improvements (55% FY reduction) with disciplined 2026 cash-burn guidance. These positives are balanced by ongoing revenue pressures in Cell Engineering, continued GAAP losses and negative adjusted EBITDA, excess lease costs (~$54M in 2025), the planned divestiture of the Biosecurity revenue stream, and some near-term execution and adoption risks as the company scales RAC production and commercializes cloud/CapEx offerings. Overall, the company is shifting to a focused, investment-led growth strategy with improved financial discipline but still faces material near-term revenue and profitability headwinds.View all DNA earnings summariesDNA Revenue Breakdown
57.08% Cell Engineering
42.92% Biosecurity
DNA Stock 12 Month Forecast
Average Price Target
$8.50
▼(-4.06% Downside)
Technical Analysis
Niagen Bioscience
―
Monopar Therapeutics Inc
―
Lyell Immunopharma
―
Jade Biosciences
―
AbSci
―
Ownership Overview
3.43% Insiders
17.44% Mutual Funds
2.11% Other Institutional Investors
62.43% Public Companies and Individual Investors